
To assess the change in the cost of diabetes medication attributable to moderate weight loss in patients with Type 2 zzso 

zzso data collected annually from zzso patients participating in the zzso community-based zzso Diabetes Study were examined to determine whether moderate weight loss zzso zzso of initial body zzso was independently associated with diabetes medication cost during 4 years' zzso 

Overall, the weight of the cohort decreased significantly during zzso zzso zzso years' follow-up by zzso zzso zzso zzso zzso zzso zzso baseline body zzso trend P zzso zzso weight loss was achieved by zzso zzso improved significantly in the group with moderate weight loss compared with the group without moderate weight loss zzso zzso 16 zzso zzso zzso zzso zzso 0 zzso 17 zzso zzso zzso zzso P zzso zzso Mean zzso zzso confidence zzso diabetes medication costs were zzso zzso during zzso As the cost distribution was highly zzso and contained zzso it was square root zzso transformed before multiple linear zzso zzso The most zzso model of baseline associates of zzso medication zzso included zzso control, diabetes treatment, diabetes zzso zzso zzso blood pressure, serum HDL cholesterol zzso taking zzso medication and age zzso zzso zzso zzso zzso After adjusting for these zzso zzso medication zzso was zzso associated with moderate weight loss zzso zzso zzso After entering average values for the cohort into the model, the cost of diabetes medications between baseline and fourth review for an average patient with no weight loss was zzso compared with zzso for a patient who attained moderate weight loss, a saving of zzso zzso 

These data highlight the economic and clinical benefits of moderate weight loss in Type 2 zzso 

